PMID- 19236192
OWN - NLM
STAT- MEDLINE
DCOM- 20090519
LR  - 20190917
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 10
IP  - 2
DP  - 2009 Feb
TI  - Vascular and metabolic effects of angiotensin II receptor blockers.
PG  - 173-89
LID - 10.1517/14656560802653180 [doi]
AB  - Angiotensin II receptor blockers (ARBs) are widely used in patients with 
      hypertension, heart failure and type 2 diabetes mellitus (T2DM). Several large 
      clinical trials have demonstrated that these agents are effective in reducing 
      cardiovascular mortality and morbidity. These benefits are partly independent of 
      the degree of blood pressure reduction and most likely related to ARBs' 
      anti-inflammatory, metabolic and vascular effects. Clinical studies showed that 
      the anti-inflammatory effect of ARBs could be related to the dosage and/or the 
      length of the treatment. In large clinical trials, ARBs have inconsistently 
      reduced the risk of new-onset T2DM. Among ARBs, only losartan significantly 
      reduced serum uric acid levels. Moreover, it has been demonstrated that ARBs 
      improve endothelial dysfunction in patients with hypertension and/or coronary 
      artery disease (CAD), while all but one of the studies proved that these agents 
      could usually, after 6-12 months of therapy, induce regression of vascular 
      hypertrophy in hypertensive patients. These positive effects could be relevant to 
      vascular protection and, together with the blood pressure reduction, constitute 
      the background of the improved outcome observed in clinical studies on mortality 
      and/or morbidity in hypertensive, high-risk and CAD patients. The clinical 
      significance of the different potency of ARBs needs to be investigated further in 
      specific and adequately powered trials.
FAU - Barra, Silvia
AU  - Barra S
AD  - Antonio Cardarelli Hospital, Cardiology Unit, 9, Via Antonio Cardarelli, 80131 
      Napoli, Naples, Italy.
FAU - Vitagliano, Alice
AU  - Vitagliano A
FAU - Cuomo, Vittoria
AU  - Cuomo V
FAU - Vitagliano, Giancarlo
AU  - Vitagliano G
FAU - Gaeta, Giovanni
AU  - Gaeta G
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Angiotensin II Type 1 Receptor Blockers)
SB  - IM
MH  - *Angiotensin II Type 1 Receptor Blockers/pharmacology/therapeutic use
MH  - Cardiovascular Diseases/*drug therapy/metabolism
MH  - Carotid Stenosis/drug therapy/metabolism
MH  - Coronary Disease/drug therapy/metabolism
MH  - Diabetes Mellitus, Type 2/*drug therapy/metabolism/prevention & control
MH  - Endothelium, Vascular/drug effects/metabolism/physiopathology
MH  - Heart Failure/drug therapy/metabolism
MH  - Humans
MH  - Hypertension/drug therapy/metabolism
MH  - Inflammation/metabolism/prevention & control
RF  - 100
EDAT- 2009/02/25 09:00
MHDA- 2009/05/20 09:00
CRDT- 2009/02/25 09:00
PHST- 2009/02/25 09:00 [entrez]
PHST- 2009/02/25 09:00 [pubmed]
PHST- 2009/05/20 09:00 [medline]
AID - 10.1517/14656560802653180 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2009 Feb;10(2):173-89. doi: 10.1517/14656560802653180.